Milan, Italy (December 12, 2023)
Today, MgShell, a MedTech company that aspires to inspire a change in ophthalmology by developing a magnesium-based drug delivery platform capable of reshaping patient care and enhancing treatment adherence for patients suffering from retinal diseases, announced its winning of the GoBeyond competition promoted by Sisal.
The advisory journey with one the GoBeyond partners and the equity-free contribution of €50,000 provided by Sisal will facilitate the enhancement of the project’s social impact by funding specific activities aimed at validating new unmet clinical needs and applications. This aligns with the company’s development plan. Here some of the most important news:
- Wired – Una startup per la maculopatia vince il premio Sisal
- Wired – MgShell vince la startup competition 2023 di GoBeyond
- Il Sole 24 Ore – L’innovazione è sempre più responsabile
- Il Sole 24 Ore – Sisal-GoBeyond: MgShell vincitrice della Call for Ideas 2023
- Askanews VIDEO– Sisal-GoBeyond: MgShell vincitrice della Call for Ideas 2023
- Startupitalia – Gobeyond 2023, MgShell vince la Call for ideas: è la startup che rivoluziona la cura per la maculopatia
- Startupitalia – Gobeyond 2023, le startup che hanno lasciato il segno
- Repubblica.it – Sisal Talk: premiazione Call for ideas di GoBeyond 2023
- Italian Tech – Sisal Talk: premiazione GoBeyond 2023
About MgShell:
MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.
